Polyclonal hyperviscosity syndrome in IgG4‐related disease and associated conditions

By  

Clinical Case Reports, Vol. 3, Iss. 4, 2015-04 ,pp. : 217-226

John Wiley & Sons Inc

Access to resources Recommend Favorite

IgG, IgM and IgA antibody responses against immediate-early, early and late human cytomegalovirus proteins in patients with HCMV infections

By Segondy M.   Salhi S.L.  

Serodiagnosis and Immunotherapy in Infectious Disease, Vol. 7, Iss. 3, 1995-09 ,pp. : 121-128

Elsevier

Access to resources Recommend Favorite

Omalizumab: Anti-IgE monoclonal antibody E25, E25, Humanised anti-IgE MAb, IGE 025, Monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25

By  

BioDrugs, Vol. 16, Iss. 5, 2002-01 ,pp. : 380-386

Adis International

Access to resources Recommend Favorite

Specific IgG 1 avidity maturation after rubella vaccination: A comparison with avidity maturation after primary infection with wild rubella virus

By Thomas H.I.J.   Charlett A.   Cubie H.A.  

Serodiagnosis and Immunotherapy in Infectious Disease, Vol. 7, Iss. 2, 1995-06 ,pp. : 75-80

Elsevier

Access to resources Recommend Favorite

The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response

By  

Clinical Case Reports, Vol. 6, Iss. 1, 2018-01 ,pp. : 96-102

John Wiley & Sons Inc

Access to resources Recommend Favorite